Troutman Pepper Advises Cardiol Therapeutics in Closing of Over-Allotment Option
October 23, 2024
October 23, 2024
ATLANTA, Georgia, Oct. 23 -- Troutman Pepper, a law firm, issued the following news:
WASHINGTON, D.C. - Troutman Pepper client Cardiol Therapeutics Inc., a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, recently announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the company (the "Commo . . .
WASHINGTON, D.C. - Troutman Pepper client Cardiol Therapeutics Inc., a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, recently announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the company (the "Commo . . .